Mabworks’ Obexelimab β Wins NMPA Approval as First Domestic NMOSD Therapy
Beijing Mabworks Biotech Co., Ltd. announced that the National Medical Products Administration (NMPA) has approved...
Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform
Fannkoer Biotech (Zhongshan) Co., Ltd. announced the completion of a Series B financing round exceeding...
Siemens Healthineers Deepens Mayo Clinic Partnership on AI Neurology and Precision Oncology
Siemens Healthineers AG (ETR: SHL) and Mayo Clinic announced an expansion of their strategic partnership, targeting...
VivaVision Biotech Files Hong Kong IPO to Advance Ophthalmology Pipeline
VivaVision Biotech (Zhejiang) Co., Ltd., an ophthalmology-focused biotech company founded in 2016, has submitted its...
Astellas’ VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY
Astellas Pharma Inc. (TYO: 4503) announced that its VENTANA CLDN18 (43-14A) Assay has received approval...
Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31
Genhouse Bio (Suzhou) Co., Ltd., a Viva Biotech-incubated company, announced a global collaboration agreement with...
3SBio’s Amdokitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (SHA: 688336), a subsidiary of 3SBio Inc. (HKG: 1530), announced that...
Bio-Thera’s Gotenfia Wins European Approval as Simponi Biosimilar
Bio-Thera Solutions Inc. (SHA: 688177) announced that the European Commission (EC) has approved Gotenfia (BAT2506), its...
First Imaging Raises $14.5 Million to Advance AI-Powered Intraoperative Imaging
First Imaging, a Nantong-based medical imaging equipment provider, has closed a Series B+ financing round...
CARsgen Therapeutics to Invest $54 Million in Shanghai CAR-T Manufacturing Facility
CARsgen Therapeutics Holdings Ltd. (HKG: 2171), a China-based CAR-T cell therapy specialist, announced plans to invest...
GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%
GlaxoSmithKline plc (GSK, NYSE: GSK) delivered strong 2025 financial results, with total revenues rising 7% in...
Novocure’s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play
Novocure Ltd. (NASDAQ: NVCR), Zai Lab Ltd.’s (NASDAQ: ZLAB, HKG: 9688) Swiss oncology partner, announced FDA clearance for...
China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China
China Medical System Holdings Limited (HKG: 0867) announced a licensing agreement with Teikoku Seiyaku Co., Ltd.,...
Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh
Organon & Co. (NYSE: OGN) announced fourth quarter and full-year 2025 financial results, with total revenue...
Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise
Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294), a pioneer in cardiorenal metabolic syndrome treatment in China,...
Sanofi Appoints Belén Garijo as New CEO to Drive R&D Innovation and Productivity
Sanofi (NASDAQ: SNY) announced a leadership transition, with Paul Hudson stepping down as Chief Executive Officer...
Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline
Shenzhen Immunofoco Biotechnology Co., Ltd., an innovative cell therapy developer, has submitted its IPO application...
Amgen’s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis
Amgen Inc. (NASDAQ: AMGN) announced that the European Commission (EC) has approved UPLIZNA (inebilizumab) as an...
Innovent Biologics Initiates Phase 3 HeriCare-Breast01 Study for IBI354 in HER2+ Breast Cancer
Innovent Biologics, Inc. (HKG: 1801) announced first patient dosing in the pivotal Phase 3 HeriCare-Breast01 study...
Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals
Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) has entered a landmark licensing agreement with Madrigal...